Charles Schwab Investment Management Inc Athira Pharma, Inc. Transaction History

Charles Schwab Investment Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$2.36 - $3.59 $191,726 - $291,651	-81,240 Reduced 85.43%	13,857 $40,000
Q1 2023 May 11, 2023	BUY	$2.26 - $4.22 $14,226 - $26,564	6,295 Added 7.09%	95,097 $237,000
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $9,329 - $45,729	3,405 Added 3.99%	88,802 $271,000
Q1 2022 May 13, 2022	BUY	$8.96 - $13.51 $7,589 - $11,442	847 Added 1.0%	85,397 $1.15 Million
Q4 2021 Feb 11, 2022	BUY	$9.17 - $16.39 $25,538 - $45,646	2,785 Added 3.41%	84,550 $1.1 Million
Q3 2021 Nov 16, 2021	SELL	$9.15 - $11.09 $642,522 - $778,750	-70,221 Reduced 46.2%	81,765 $767,000
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $416,952 - $849,784	40,718 Added 36.59%	151,986 $1.56 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $465,054 - $819,210	27,518 Added 32.86%	111,268 $2.05 Million
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $1.38 Million - $2.87 Million	83,750 New	83,750 $2.87 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.